Notwithstanding promising clinical results, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing significant opposition from PBMs. The insurers are frequently building limitations to reimbursement, including high price restrictions and prior authorization that limit consumer opportunity. Anal